Chinese Cancer Intervention Market to Reach Double-Digits (13.8% CAGR)

July 20, 2017

Wellesley, Mass., Jul 20, 2017 – The Chinese cancer intervention market is big, fast-growing, and dominated by drug and equipment suppliers from outside China,  all important considerations for pharmaceutical companies in North America, Europe and other developed regions seeking strong growth and high profits, reports The Chinese Market for Cancer Intervention.

Many of the world’s leading drug makers and medical equipment manufacturers have set up research and development centers in China, according to the new BCC Research report. Since 2005, Pfizer, Novartis, Roche, Sanofi, MSD, and other companies have established these centers not only for drug development, but also to facilitate partnerships with Chinese academic institutions and organizations, to train physicians, and to hold academic and promotion events.  The June 2017 report also predicts the Chinese market to top $89.3 billion, up from an estimated $46.7 billion in 2017.

Meanwhile, most Chinese companies continue to develop generic drugs and inexpensive versions of medical equipment first developed by their foreign counterparts. Chinese companies have made some progress in developing Referenced Listed Drugs and advanced medical equipment. For example, elemene injection, an anti-tumor drug derived from a traditional Chinese drug, was first developed by the China-based Dalian Holley Kingkong Pharmaceutical.

Research Highlights

  • DNA sequencing for cancer screening, early detection, diagnosis, therapy guidance, and monitoring will have strong growth, especially for lung cancer, colorectal cancer, breast cancer, and leukemia/lymphoma.
  • Paclitaxel will continue to dominate the anti-tumor market, reaching $2.7 billion by 2022 with a 13.2% CAGR.
  • Roche has the largest share of the Chinese cancer intervention market, with sales of over $2.5 billion for drugs used for cancer treatment in 2016, with sales values measured at the end-user level.

"The cancer treatment segment has approximately 94% of the Chinese cancer intervention market," says analyst Jason Chen, who authored the report. "China’s technologies and products relies heavily on big pharmaceutical companies and medical equipment manufacturers from other countries. These markets see robust international competition."

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at

The Chinese Market for Cancer Intervention( PHM179A )
Publish Date: Jun 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.